Plasma Cell Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PLS009 MIFTS: 65	Plasma Cell Neoplasm Categories: Blood diseases, Cancer diseases, Immune diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Plasma Cell Neoplasm

MalaCards integrated aliases for Plasma Cell Neoplasm:

Name: Plasma Cell Neoplasm ¹¹ ²⁸ ¹⁴ ¹⁶ ⁷¹

Plasma Cell Dyscrasia ¹¹ ⁵ ⁷¹

Paraproteinemias ⁴³ ⁷¹

Plasma Cells Dyscrasia ³³

Plasma Cell Tumours ³³

Plasma Cell Tumour ¹¹

Plasmacytic Tumor ¹¹

Multiple Myeloma ⁷¹

Plasmacytoma ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Immune diseases Blood diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Mature B-cell neoplasms

Plasma cell neoplasms

Plasma cell neoplasm, unspecified

External Ids:

Disease Ontology ¹¹ DOID:6536

MeSH ⁴³ D010265

SNOMED-CT ⁶⁸ 71390001

EFO ¹⁶ EFO_0000200

ICD11 ³³ 1219149360 1219149360/unspecified

UMLS ⁷¹ C0026764 C0030489 C0032131 more

Sources

Summaries for Plasma Cell Neoplasm

Disease Ontology: ¹¹ A mature B-cell neoplasm that is composed of plasma cells.

MalaCards based summary: Plasma Cell Neoplasm, also known as plasma cell dyscrasia, is related to plasma cell leukemia and myeloma, multiple. An important gene associated with Plasma Cell Neoplasm is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Coenzyme M and Phentolamine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and bone, and related phenotypes are Decreased viability and Decreased shRNA abundance

Sources

Related Diseases for Plasma Cell Neoplasm

Diseases related to Plasma Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 463)

#	Related Disease	Score	Top Affiliating Genes
1	plasma cell leukemia	32.8	FGFR3 DIS3 CDK4 B2M
2	myeloma, multiple	32.6	YAP1 TP53 TET2 NRAS MYD88 LIG4
3	myeloproliferative neoplasm	31.5	TET2 HRAS FLT3 FGFR3 DNMT3A B2M
4	polycythemia vera	31.3	TP53 TET2 IDH1 HRAS DNMT3A ATM
5	myelofibrosis	31.3	TP53 TET2 IDH1 HRAS FLT3 DNMT3A
6	smoldering myeloma	31.2	FGFR3 DIS3 CRBN B2M
7	monoclonal gammopathy of uncertain significance	31.0	TP53 MYD88 FGFR3 DIS3 CRBN B2M
8	myelodysplastic syndrome	31.0	TP53 TET2 NRAS KRAS IDH1 HRAS
9	lymphoma	30.9	TP53 TET2 MYD88 CDKN2C CDK4 ATM
10	leukemia, chronic lymphocytic	30.9	TP53 TET2 NRAS MYD88 KRAS HRAS
11	renal cell carcinoma, nonpapillary	30.8	TP53 NRAS KRAS HRAS FLT3 DNMT3A
12	leukemia	30.8	TP53 NRAS IDH1 FLT3 DNMT3A ATM
13	leukemia, chronic myeloid	30.8	TP53 TET2 NRAS KRAS HRAS FLT3
14	essential thrombocythemia	30.8	TP53 TET2 IDH1 FLT3 DNMT3A
15	leukemia, acute myeloid	30.7	TP53 TET2 NRAS KRAS IDH1 HRAS
16	carcinosarcoma	30.7	TP53 KRAS HRAS
17	lymphoma, non-hodgkin, familial	30.6	TP53 NRAS MYD88 FLT3 CDKN2C B2M
18	peripheral nervous system disease	30.6	TP53 NRAS KRAS HRAS CDK4 B2M
19	cholangiocarcinoma	30.6	YAP1 TP53 KRAS IDH1
20	glioblastoma	30.6	TP53 NRAS KRAS IDH1 HRAS DNMT3A
21	skin disease	30.6	TP53 NRAS MYD88 KRAS HRAS FGFR3
22	mantle cell lymphoma	30.6	TP53 MYD88 FLT3 CRBN CDKN2C CDK4
23	acute leukemia	30.5	KRAS FLT3 DNMT3A CDKN2C
24	poems syndrome	11.6
25	refractory plasma cell neoplasm	11.4
26	light chain deposition disease	11.3
27	immunoglobulin heavy chain amyloidosis	11.3
28	indolent plasma cell myeloma	11.1
29	polyneuropathy	10.8
30	blastoma	10.6	TP53 KRAS HRAS
31	serous cystadenocarcinoma	10.6	TP53 KRAS HRAS
32	vaginal carcinosarcoma	10.6	TP53 KRAS HRAS
33	cystadenocarcinoma	10.6	YAP1 TP53 KRAS
34	liver angiosarcoma	10.6	TP53 KRAS HRAS
35	cystadenofibroma	10.6	TP53 KRAS HRAS
36	endosalpingiosis	10.6	TP53 KRAS HRAS
37	appendix adenocarcinoma	10.6	TP53 KRAS HRAS
38	bladder transitional cell papilloma	10.6	TP53 HRAS FGFR3
39	large cell carcinoma with rhabdoid phenotype	10.6	TP53 KRAS HRAS
40	pancreatic signet ring cell adenocarcinoma	10.6	TP53 KRAS HRAS
41	blood protein disease	10.6	TP53 FGFR3 DIS3 B2M
42	signet ring cell adenocarcinoma	10.6	TP53 KRAS HRAS
43	biliary tract benign neoplasm	10.6	TP53 KRAS HRAS
44	pleomorphic carcinoma	10.6	TP53 KRAS HRAS
45	small intestine adenocarcinoma	10.6	TP53 KRAS HRAS
46	mismatch repair cancer syndrome	10.6	TP53 KRAS HRAS ATM
47	papillary adenoma	10.6	TP53 KRAS HRAS
48	acneiform dermatitis	10.6	NRAS KRAS HRAS
49	ovarian serous cystadenocarcinoma	10.6	TP53 NRAS KRAS HRAS B2M
50	lung carcinoma in situ	10.6	TP53 KRAS HRAS

Comorbidity relations with Plasma Cell Neoplasm via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease	Acute Cystitis
Acute Kidney Failure	Bronchitis
Chronic Kidney Disease	Deficiency Anemia
Heart Disease	Monoclonal Paraproteinemia
Neutropenia	Osteoporosis

Graphical network of the top 20 diseases related to Plasma Cell Neoplasm:

Sources

Symptoms & Phenotypes for Plasma Cell Neoplasm

GenomeRNAi Phenotypes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

²⁵ (show all 21)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.9	AURKA HRAS KRAS
2	Decreased viability	GR00055-A-2	10.9	AURKA HRAS KRAS
3	Decreased viability	GR00055-A-3	10.9	KRAS
4	Decreased viability	GR00106-A-0	10.9	KRAS
5	Decreased viability	GR00173-A	10.9	FLT3
6	Decreased viability	GR00221-A-1	10.9	AURKA CYLD FGFR3 HRAS KRAS CDKN2C
7	Decreased viability	GR00221-A-2	10.9	AURKA CYLD FGFR3 HRAS KRAS
8	Decreased viability	GR00221-A-3	10.9	FGFR3 HRAS NRAS
9	Decreased viability	GR00221-A-4	10.9	AURKA FLT3
10	Decreased viability	GR00231-A	10.9	AURKA
11	Decreased viability	GR00249-S	10.9	AURKA CYLD FGFR3 CDKN2C
12	Decreased viability	GR00301-A	10.9	CYLD KRAS CDKN2C
13	Decreased viability	GR00381-A-1	10.9	KRAS
14	Decreased viability	GR00402-S-2	10.9	AURKA CYLD
15	Decreased shRNA abundance	GR00251-A-1	10.36	B2M CDK4 CRBN CYLD FLT3 IDH1
16	Decreased shRNA abundance	GR00251-A-2	10.36	B2M CDK4 CRBN CYLD FLT3 IDH1
17	no effect	GR00402-S-1	10.15	ATM AURKA B2M CDK4 CDKN2C CRBN
18	no effect	GR00402-S-2	10.15	ATM B2M CDK4 CDKN2C CRBN FGFR3
19	Decreased viability in pancreas lineage	GR00235-A	9.56	DNMT3A FLT3 IDH1 TP53
20	Reduced mammosphere formation	GR00396-S	9.5	ATM CDK4 DNMT3A HRAS KRAS MYD88
21	Increased senescence-associated beta-galactosidase protein expression after pRB stimulation	GR00230-A-2	9.02	FLT3

MGI Mouse Phenotypes related to Plasma Cell Neoplasm:

⁴⁵ (show all 20)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.51	ATM AURKA B2M CDK4 CDKN2C CRBN
2	homeostasis/metabolism	MP:0005376	10.5	ATM B2M CDK4 CDKN2C CRBN CYLD
3	neoplasm	MP:0002006	10.49	ATM AURKA B2M CDK4 CDKN2C CYLD
4	endocrine/exocrine gland	MP:0005379	10.43	ATM AURKA B2M CDK4 CDKN2C CYLD
5	nervous system	MP:0003631	10.42	ATM B2M CDK4 CDKN2C CRBN DNMT3A
6	cellular	MP:0005384	10.4	ATM AURKA B2M CDK4 CDKN2C CYLD
7	immune system	MP:0005387	10.39	ATM AURKA B2M CDK4 CDKN2C CRBN
8	behavior/neurological	MP:0005386	10.33	ATM CDK4 CDKN2C CRBN CYLD DIS3
9	digestive/alimentary	MP:0005381	10.29	B2M CDK4 CRBN CYLD FGFR3 HRAS
10	liver/biliary system	MP:0005370	10.26	B2M CDK4 CRBN KRAS LIG4 MYD88
11	cardiovascular system	MP:0005385	10.26	ATM B2M CDK4 CDKN2C CRBN HRAS
12	no phenotypic analysis	MP:0003012	10.24	AURKA FGFR3 FLT3 HRAS KRAS MYD88
13	renal/urinary system	MP:0005367	10.22	CDK4 CDKN2C FGFR3 HRAS KRAS MYD88
14	reproductive system	MP:0005389	10.11	ATM AURKA B2M CDK4 CDKN2C DNMT3A
15	hematopoietic system	MP:0005397	10.11	ATM AURKA B2M CDK4 CDKN2C CRBN
16	respiratory system	MP:0005388	10.06	CDKN2C CYLD FGFR3 HRAS IDH1 KRAS
17	skeleton	MP:0005390	10.06	AURKA CDK4 DNMT3A FGFR3 FLT3 HRAS
18	vision/eye	MP:0005391	9.96	AURKA CDK4 CRBN DIS3 FGFR3 KRAS
19	mortality/aging	MP:0010768	9.96	ATM AURKA B2M CDK4 CDKN2C CRBN
20	integument	MP:0010771	9.4	ATM B2M CDK4 CDKN2C CYLD FGFR3

Sources

Drugs & Therapeutics for Plasma Cell Neoplasm

Drugs for Plasma Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 601)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Coenzyme M

Approved, Investigational

Phase 4

3375-50-6

598 23662354

Phentolamine

Approved

Phase 4

50-60-2

5775

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Dimethyl sulfoxide

Approved, Vet_approved

Phase 4

67-68-5

679

Iron

Approved

Phase 4

7439-89-6

29936

Pirarubicin

Investigational

Phase 4

72496-41-4

4844

Calcium, Dietary

Phase 4

Epoetin Alfa

Phase 4

Hematinics

Phase 4

Chrysarobin

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Lomustine

Approved, Investigational

Phase 3

13010-47-4

3950

Apixaban

Approved

Phase 3

503612-47-3

10182969

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Amitriptyline

Approved

Phase 3

50-48-6

2160

Baclofen

Approved

Phase 3

1134-47-0

2284

Ketamine

Approved, Vet_approved

Phase 3

6740-88-1, 1867-66-9

3821

Sirolimus

Approved, Investigational

Phase 3

53123-88-9

5284616 6436030

Darbepoetin alfa

Approved, Investigational

Phase 3

209810-58-2

Pamidronic acid

Approved

Phase 3

40391-99-9

4674

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 3

9005-49-6

22833565 9812414 772

Ciprofloxacin

Approved, Investigational

Phase 3

85721-33-1, 93107-08-5

2764

Amphotericin B

Approved, Investigational

Phase 3

1397-89-3

5280965

Nystatin

Approved, Vet_approved

Phase 3

1400-61-9

11953884

Deoxycholic acid

Approved

Phase 3

83-44-3

222528

Idarubicin

Approved

Phase 3

58957-92-9

42890

Trimethoprim

Approved, Vet_approved

Phase 3

738-70-5

5578

Sulfamethoxazole

Approved

Phase 3

723-46-6

5329

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Dextromethorphan

Approved

Phase 3

125-71-3

5362449 5360696

Vancomycin

Approved

Phase 3

1404-90-6

14969

Tazobactam

Approved

Phase 3

89786-04-9

123630

Piperacillin

Approved

Phase 3

66258-76-2

43672

Denosumab

Approved

Phase 3

615258-40-7

Epirubicin

Approved

Phase 3

56420-45-2

41867

Carvedilol

Approved, Investigational

Phase 3

72956-09-3

2585

Enalaprilat

Approved

Phase 3

76420-72-9

6917719 5462501

Enalapril

Approved, Vet_approved

Phase 3

75847-73-3

40466924 5388962 5362032

Modafinil

Approved, Investigational

Phase 3

68693-11-8

4236

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Oxycodone

Approved, Illicit, Investigational

Phase 3

76-42-6

5284603

Morphine

Approved, Investigational

Phase 3

57-27-2

5288826

Rivaroxaban

Approved

Phase 2, Phase 3

366789-02-8

9875401

Ketorolac

Approved

Phase 3

74103-06-3, 66635-83-4

3826

Hydrocodone

Approved, Illicit, Investigational

Phase 3

125-29-1

5284569

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Interventional clinical trials:

(show top 50) (show all 3030)

#	Name	Status	NCT ID	Phase	Drugs
1	Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study	Unknown status	NCT02577783	Phase 4	PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
2	A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma.	Unknown status	NCT01868828	Phase 4	PAD;VCD
3	Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients	Unknown status	NCT04348006	Phase 4	Bortezomib 3.5 MG
4	An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma	Unknown status	NCT02559154	Phase 4	Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
5	Stage I Multiple Myeloma Treatment	Unknown status	NCT00733538	Phase 4	zometa
6	Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes	Unknown status	NCT01249690	Phase 4	Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
7	Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
8	A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent	Completed	NCT03768960	Phase 4	Daratumumab
9	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy	Completed	NCT02958969	Phase 4	Apixaban
10	Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma	Completed	NCT00652041	Phase 4	Bortezomib;Thalidomide
11	Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study	Completed	NCT02268890	Phase 4	Bortezomib
12	A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases	Completed	NCT00104104	Phase 4	zoledronic acid
13	Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents	Completed	NCT03619252	Phase 4	Standard Antibacterial Prophylaxis
14	Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group	Completed	NCT01087008	Phase 4	zoledronic acid
15	A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions	Completed	NCT00029224	Phase 4	zoledronic acid
16	An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy	Completed	NCT03416374	Phase 4	Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
17	Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability	Completed	NCT00257114	Phase 4	bortezomib
18	An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation	Completed	NCT00352703	Phase 4	Kepivance (Palifermin)
19	An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures	Completed	NCT00211211	Phase 4
20	Bone Marker-directed Dosing of ZOMETA® (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma.	Completed	NCT00622505	Phase 4	zoledronic acid
21	A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma	Completed	NCT01731886	Phase 4	Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
22	A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety	Completed	NCT00434447	Phase 4	Zoledronic acid
23	The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia	Completed	NCT00524407	Phase 4	Epoetin alfa
24	A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM)	Recruiting	NCT03829371	Phase 4	Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone;Daratumumab
25	RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma	Recruiting	NCT03908138	Phase 4	RDD;VDD
26	A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma	Recruiting	NCT04217967	Phase 4	Ixazomib;Lenalidomide
27	Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel	Recruiting	NCT05201781	Phase 4	Cilta-cel
28	Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study	Recruiting	NCT03934684	Phase 4	Drug: Carfilzomib + Dexamethasone;Drug: Carfilzomib + Lenalidomide + Dexamethasone
29	A Multi-center, Open-label, Single-arm Clinical Study of Ixazomib/Pomalidomide/Dexamethasone (IxaPD) in the Treatment of Patients With Relapsed Multiple Myeloma	Recruiting	NCT04989140	Phase 4	Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
30	A Single Arm, Open Label, Interventional Study Assessing the Mobilization Efficacy and Safety of Plerixafor in Combination With G- CSF in Multiple Myeloma Patients for Autologous Transplantation	Recruiting	NCT05087212	Phase 4	plerixafor + G-CSF
31	Influenza Vaccination in Plasma Cell Dyscrasias	Active, not recruiting	NCT04080531	Phase 4
32	Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial	Active, not recruiting	NCT02286830	Phase 4	Zoledronic acid
33	An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)	Active, not recruiting	NCT03173092	Phase 4	Ixazomib;Lenalidomide;Dexamethasone
34	Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day: Reduction in Costs, Same Efficacy? A PKPD Bioequivalence Pilot Study; the POMAlternative Study	Not yet recruiting	NCT05555329	Phase 4	Pomalidomide 4 mg every day in cycle 1;Pomalidomide 4 mg every other day in cycle 2;Pomalidomide 2 mg every day in cycle 2;Pomalidomide 2 mg every day in cycle 3;Pomalidomide 4 mg every other day in cycle 3
35	A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation	Not yet recruiting	NCT05545202	Phase 4
36	Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury: a Prospective Cohort Study	Not yet recruiting	NCT05429515	Phase 4	Chemotherapy
37	Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years	Terminated	NCT02773550	Phase 4	Bortezomib;Melphalan;Prednisone
38	Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment	Terminated	NCT02608060	Phase 4	Epoetin Beta
39	Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy	Terminated	NCT01100879	Phase 4	Ferric carboxymaltose
40	Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA)	Withdrawn	NCT02920190	Phase 4	Liraglutide
41	An Open-Label, Non-Comparative, Two-Cohort, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Pomalidomide and Dexamethasone (IPd, Cohort A) or With Lenalidomide and Dexamethasone (IRd, Cohort B) in Patients With Relapsed/Refractory Multiple Myeloma Previously Receiving a Parenteral Proteasome Inhibitor-based Treatment Regimen (US MM-7)	Withdrawn	NCT05183139	Phase 4	Ixazomib;Pomalidomide;Lenalidomide;Dexamethasone
42	Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.	Withdrawn	NCT00242528	Phase 4	Zoledronic acid
43	Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma	Withdrawn	NCT01410929	Phase 4
44	Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue.	Unknown status	NCT00747877	Phase 3	cyclophosphamide;melphalan
45	Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia	Unknown status	NCT00482716	Phase 3
46	A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma	Unknown status	NCT00014339	Phase 3	Wobe-Mugos E;melphalan;prednisone
47	A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma	Unknown status	NCT00028886	Phase 3	cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
48	A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse	Unknown status	NCT00002989	Phase 3	busulfan;cyclophosphamide;idarubicin;melphalan
49	A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma	Unknown status	NCT00003603	Phase 3	cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
50	MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL	Unknown status	NCT00002599	Phase 3	carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate

Search NIH Clinical Center for Plasma Cell Neoplasm

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Aldesleukin

bortezomib

carfilzomib

Carmustine

Cisplatin

CISPLATIN PWDR

Cyclophosphamide

Interferon Alfa-2a

Interferon Alfa-2b

INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED

interferon alfacon-1

Interferon gamma-1b

Interferons

Melphalan

Melphalan hydrochloride

panobinostat

peginterferon alfa-2a

peginterferon alfa-2b

Procarbazine

Procarbazine Hydrochloride

Recombinant interferon beta-1a

Recombinant interferon beta-1b

Thalidomide

ZOLEDRONIC

zoledronic acid

Cochrane evidence based reviews: paraproteinemias

Sources

Genetic Tests for Plasma Cell Neoplasm

Genetic tests related to Plasma Cell Neoplasm:

#	Genetic test	Affiliating Genes
1	Plasma Cell Neoplasm ²⁸

Sources

Anatomical Context for Plasma Cell Neoplasm

Organs/tissues related to Plasma Cell Neoplasm:

MalaCards : T Cells, Bone Marrow, Bone, Nk Cells, Myeloid, Breast, Kidney

Sources

Publications for Plasma Cell Neoplasm

Articles related to Plasma Cell Neoplasm:

(show top 50) (show all 1649)

#	Title	Authors	PMID	Year
1	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
2	Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. ⁵	Goriely A...Wilkie AO	19855393	2009
3	An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation. ⁵	Garcia-Vargas A...Happle R	18642369	2008
4	Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. ⁵	Hafner C...Hartmann A	16841094	2006
5	Thanatophoric dysplasia type 2 with encephalocele during the second trimester. ⁵	Li D...Tang X	16752380	2006
6	Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. ⁵	Logie A...Radvanyi F	15772091	2005
7	Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. ⁵	Hyland VJ...Glass IA	12833394	2003
8	The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. ⁵	Lievens PM...Liboi E	12624096	2003
9	Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). ⁵	Intini D...Neri A	11529856	2001
10	Prenatal diagnosis of thanatophoric dysplasia by mutational analysis of the fibroblast growth factor receptor 3 gene and a proposed correction of previously published PCR results. ⁵	Sawai H...Koyama K	10073901	1999
11	Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. ⁵	Wilcox WR...Rimoin DL	9677066	1998
12	Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. ⁵	Chesi M...Bergsagel PL	9207791	1997
13	Japanese cases of type 1 thanatophoric dysplasia exclusively carry a C to T transition at nucleotide 742 of the fibroblast growth factor receptor 3 gene. ⁵	Pokharel RK...Matsuo M	8858131	1996
14	Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. ⁵	Tavormina PL...Wasmuth JJ	7773297	1995
15	Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing. ⁶²	Chow S...Pugh TJ	36328595	2023
16	Extramedullary plasmacytoma of the uterine cervix arising in an asymptomatic 46-year-old female. ⁶²	Wiebe N...McGee J	36277031	2022
17	Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM). ⁶²	Hatic H...Goyal G	36270091	2022
18	A germline exome analysis reveals harmful POT1 variants in multiple myeloma patients and families. ⁶²	Hakkarainen M...Wartiovaara-Kautto U	36467798	2022
19	How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells. ⁶²	van de Donk NWCJ	36450104	2022
20	LOCALIZED CONJUNCTIVAL AL-AMYLOID DEPOSITS SECONDARY TO A RETINAL DETACHMENT SURGERY RADIAL EXPLANT. ⁶²	Mudhar HS...Stafanous S	33229921	2022
21	A POEMS syndrome patient with idiopathic non-cirrhotic portal hypertension received the transjugular intrahepatic portosystemic shunt: a case report and literature review. ⁶²	Chen Y...Zhang H	36412305	2022
22	Pediatric Plasma Cell Neoplasms: A Population-Based Study. ⁶²	Loap P...Kirova Y	35941071	2022
23	FDG PET-MRI evaluation of synchronous gallbladder adenocarcinoma and POEMS syndrome. ⁶²	Ataei F...Parent EE	36132063	2022
24	Clinical Presentation and Outcome of Sinonasal Extraosseous Plasmacytoma in Denmark: A Nationwide Cohort From 1980 to 2017. ⁶²	Eriksen PRG...von Buchwald C	36433794	2022
25	Comprehensive Diagnosis and Management of POEMS Syndrome. ⁶²	D'Sa S...Lunn MP	36340912	2022
26	Low-grade B-cell lymphoma of the central nervous system with plasmacytic differentiation and amyloid deposition. ⁶²	Lopez G...Vinters HV	36451532	2022
27	Coexistence of TEMPI syndrome and leukocytoclastic vasculitis successfully treated with autologous stem cell transplantation. ⁶²	Nappi D...Sykes D	36467823	2022
28	Light Chain Amyloidosis Presenting as a Septic Shock: A Case Report and Review of Literature. ⁶²	Bazzi T...Al-Rammahi A	36381809	2022
29	An Analysis of M-protein in Plasma cell Dyscrasia Patients Identifies that IgG Lambda Subtype is More Commonly Associated with Normal Serum Free Light Chain (SFLC) Ratio. ⁶²	Singh MK...Nityanand S	36262785	2022
30	Two cases of extramedullary plasmacytoma of the small intestine presenting with ileus: A case report. ⁶²	Park KB...Seo AN	36221423	2022
31	Dual Expression of Immunoglobulin Light Chains in Plasma Cell Myeloma: A Case Report and Literature Review. ⁶²	Suresh J...Torlakovic EE	36314594	2022
32	Light Chain Testing Abnormalities Among Patients With Transthyretin Amyloid Cardiomyopathy Referred for Technetium-99m Pyrophosphate Imaging. ⁶²	Alreshq R...Ruberg FL	36028388	2022
33	Extramedullary plasmacytoma with colonic involvement: experience in a tertiary hospital. ⁶²	Mesa Lopez MJ...Egea Valenzuela J	35469400	2022
34	Persistent diarrhea with petechial rash - unusual pattern of light chain amyloidosis deposition on skin and gastrointestinal biopsies: A case report. ⁶²	Bilton SE...Grider DJ	36246794	2022
35	Epstein-Barr Virus-Positive Plasma Cell Neoplasm of Nasal Cavity in an Immunocompetent Adult. ⁶²	He L...Chen M	35925565	2022
36	Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis. ⁶²	Scholl AR...Carlsen ED	35993812	2022
37	A Novel Integrated Approach for Cytogenomic Evaluation of Plasma Cell Neoplasms. ⁶²	Aarabi M...Yatsenko SA	35940519	2022
38	Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasms. ⁶²	Qiu L...Lin P	36244464	2022
39	Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma. ⁶²	Zhou T...Pittaluga S	35650679	2022
40	Long-Term Complete Clinical and Hematological Response With Bortezomib: The Report of a Case With TEM(P)I Syndrome and a Review of the Literature. ⁶²	Undar L...Alpsoy E	35624059	2022
41	18F-Fluciclovine PET/CT: A Potential Imaging Biomarker for the Evaluation of Multiple Myeloma. ⁶²	Marcus C...Tajmir SH	35930716	2022
42	Testicular Plasmacytoma Masking as Epididymo-orchitis in a Known Multiple Myeloma Patient. ⁶²	Vusqa UT...Samhouri Y	36060019	2022
43	Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. ⁶²	Gustine JN...Sanchorawala V	35731907	2022
44	Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group. ⁶²	Ganzel C...Cohen YC	36075048	2022
45	Severe bleeding diathesis as onset of light-chain amyloidosis: combined excessive fibrinolysis and acquired von Willebrand disease in a young patient. ⁶²	Pardos-Gea J...Gironella M	36165074	2022
46	The Prevalence of Epstein-Barr Virus in Plasma Cell Neoplasms is Higher in HIV-Positive Individuals. ⁶²	Penzhorn IH...Sher-Locketz C	35912479	2022
47	Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation. ⁶²	Elnaggar M...Lagana A	35978321	2022
48	Multiple Myeloma Uncovered Under Excessive Antacid and Chronic NSAID Use in a Young Female. ⁶²	Fujikawa P...Patel K	36072215	2022
49	A case of plasma cell neoplasm-associated chronic neutrophilic leukemia with ASXL1 and JAK2V617F mutations. ⁶²	Lauw MIS...Xie Y	35419626	2022
50	Evidence-based medical treatment of POEMS syndrome. ⁶²	Khwaja J...Sive J	35934319	2022

Sources

Genes for Plasma Cell Neoplasm

Genes related to Plasma Cell Neoplasm (4 elite genes):

(show top 50) (show all 95)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TP53	Tumor Protein P53	Protein Coding	431.6	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
2	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	430.04	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
3	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	406.34	Pathogenic/Likely pathogenic ⁵ DISEASES inferred ¹⁴	7773297 8858131 9207791 (more) 9677066 10073901 11529856 12624096 12833394 15772091 16752380 16841094 18642369 19855393 26619011
4	LIG4	DNA Ligase 4	Protein Coding	403.49	Pathogenic ⁵ DISEASES inferred ¹⁴
5	B2M	Beta-2-Microglobulin	Protein Coding	32.45	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
6	DIS3	DIS3 Homolog, Exosome Endoribonuclease And 3'-5' Exoribonuclease	Protein Coding	31.38	Likely pathogenic ⁵ DISEASES inferred ¹⁴
7	CRBN	Cereblon	Protein Coding	30.78	Likely pathogenic ⁵ DISEASES inferred ¹⁴
8	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	30.68	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
9	CDKN2C	Cyclin Dependent Kinase Inhibitor 2C	Protein Coding	30.57	Likely pathogenic ⁵ DISEASES inferred ¹⁴
10	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	30.25	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
11	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	30.03	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
12	ATM	ATM Serine/Threonine Kinase	Protein Coding	30	Likely pathogenic ⁵ DISEASES inferred ¹⁴
13	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	29.85	Likely pathogenic ⁵ DISEASES inferred ¹⁴
14	TET2	Tet Methylcytosine Dioxygenase 2	Protein Coding	29.77	Likely pathogenic ⁵ DISEASES inferred ¹⁴
15	CDK4	Cyclin Dependent Kinase 4	Protein Coding	29.66	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
16	FLT3	Fms Related Receptor Tyrosine Kinase 3	Protein Coding	29.57	Likely pathogenic ⁵ DISEASES inferred ¹⁴
17	CYLD	CYLD Lysine 63 Deubiquitinase	Protein Coding	29.51	Likely pathogenic ⁵ DISEASES inferred ¹⁴
18	YAP1	Yes1 Associated Transcriptional Regulator	Protein Coding	29.41	Likely pathogenic ⁵ DISEASES inferred ¹⁴
19	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	29.26	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
20	AURKA	Aurora Kinase A	Protein Coding	29.1	Likely pathogenic ⁵ DISEASES inferred ¹⁴
21	IL7R	Interleukin 7 Receptor	Protein Coding	29.01	Likely pathogenic ⁵ DISEASES inferred ¹⁴
22	TCF3	Transcription Factor 3	Protein Coding	28.94	Likely pathogenic ⁵ DISEASES inferred ¹⁴
23	PTPN11	Protein Tyrosine Phosphatase Non-Receptor Type 11	Protein Coding	28.94	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
24	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2	Protein Coding	28.92	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
25	KMT2D	Lysine Methyltransferase 2D	Protein Coding	28.88	Likely pathogenic ⁵ DISEASES inferred ¹⁴
26	NF1	Neurofibromin 1	Protein Coding	28.82	Likely pathogenic ⁵ DISEASES inferred ¹⁴
27	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	28.77	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
28	H1-4	H1.4 Linker Histone, Cluster Member	Protein Coding	28.75	Likely pathogenic ⁵ DISEASES inferred ¹⁴
29	HDAC4	Histone Deacetylase 4	Protein Coding	28.66	Likely pathogenic ⁵ DISEASES inferred ¹⁴
30	CREBBP	CREB Binding Protein	Protein Coding	28.55	Likely pathogenic ⁵ DISEASES inferred ¹⁴
31	KMT2C	Lysine Methyltransferase 2C	Protein Coding	28.47	Likely pathogenic ⁵ DISEASES inferred ¹⁴
32	NCOR2	Nuclear Receptor Corepressor 2	Protein Coding	28.19	Likely pathogenic ⁵ DISEASES inferred ¹⁴
33	SH2B3	SH2B Adaptor Protein 3	Protein Coding	28.18	Likely pathogenic ⁵ DISEASES inferred ¹⁴
34	SGK1	Serum/Glucocorticoid Regulated Kinase 1	Protein Coding	28.16	Likely pathogenic ⁵ DISEASES inferred ¹⁴
35	LATS1	Large Tumor Suppressor Kinase 1	Protein Coding	28.15	Likely pathogenic ⁵ DISEASES inferred ¹⁴
36	TET3	Tet Methylcytosine Dioxygenase 3	Protein Coding	27.98	Likely pathogenic ⁵ DISEASES inferred ¹⁴
37	BCORL1	BCL6 Corepressor Like 1	Protein Coding	27.95	Likely pathogenic ⁵ DISEASES inferred ¹⁴
38	NKX2-1	NK2 Homeobox 1	Protein Coding	27.93	Likely pathogenic ⁵ DISEASES inferred ¹⁴
39	ARID4A	AT-Rich Interaction Domain 4A	Protein Coding	25	Likely pathogenic ⁵
40	BAP1	BRCA1 Associated Protein 1	Protein Coding	25	Likely pathogenic ⁵
41	BARD1	BRCA1 Associated RING Domain 1	Protein Coding	25	Likely pathogenic ⁵
42	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	25	Likely pathogenic ⁵	26619011
43	EIF1AX	Eukaryotic Translation Initiation Factor 1A X-Linked	Protein Coding	25	Likely pathogenic ⁵
44	ERF	ETS2 Repressor Factor	Protein Coding	25	Likely pathogenic ⁵
45	FAT1	FAT Atypical Cadherin 1	Protein Coding	25	Likely pathogenic ⁵
46	H2AC16	H2A Clustered Histone 16	Protein Coding	25	Likely pathogenic ⁵
47	H2AC17	H2A Clustered Histone 17	Protein Coding	25	Likely pathogenic ⁵
48	H3C1	H3 Clustered Histone 1	Protein Coding	25	Likely pathogenic ⁵
49	KDM5C	Lysine Demethylase 5C	Protein Coding	25	Likely pathogenic ⁵
50	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	25	Likely pathogenic ⁵	26619011

Sources

Variations for Plasma Cell Neoplasm

ClinVar genetic disease variations for Plasma Cell Neoplasm:

⁵ (show top 50) (show all 196)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	LIG4	NM_206937.2(LIG4):c.2440C>T (p.Arg814Ter)	SNV	Pathogenic	7673	rs104894419	GRCh37: 13:108861177-108861177 GRCh38: 13:108208829-108208829
2	FGFR3	NM_000142.5(FGFR3):c.1948A>G (p.Lys650Glu)	SNV	Pathogenic	16331	rs78311289	GRCh37: 4:1807889-1807889 GRCh38: 4:1806162-1806162
3	FGFR3	FGFR3, FGFR3/IGH FUSION	VAR	Pathogenic	16343		GRCh37: GRCh38:
4	KRAS	NM_004985.5(KRAS):c.35G>C (p.Gly12Ala)	SNV	Pathogenic	45122	rs121913529	GRCh37: 12:25398284-25398284 GRCh38: 12:25245350-25245350
5	TP53	NM_000546.6(TP53):c.818G>A (p.Arg273His)	SNV	Pathogenic Likely Pathogenic	12366	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
6	FGFR3	NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys)	SNV	Pathogenic/Likely Pathogenic	16332	rs121913482	GRCh37: 4:1803564-1803564 GRCh38: 4:1801837-1801837
7	TP53	NM_000546.6(TP53):c.841G>A (p.Asp281Asn)	SNV	Likely Pathogenic	376586	rs764146326	GRCh37: 17:7577097-7577097 GRCh38: 17:7673779-7673779
8	TP53	NM_000546.6(TP53):c.818G>C (p.Arg273Pro)	SNV	Likely Pathogenic	231060	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
9	TP53	NM_000546.6(TP53):c.743G>C (p.Arg248Pro)	SNV	Likely Pathogenic	237954	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
10	TP53	NM_000546.6(TP53):c.613T>C (p.Tyr205His)	SNV	Likely Pathogenic	376685	rs1057520008	GRCh37: 17:7578236-7578236 GRCh38: 17:7674918-7674918
11	TP53	NM_000546.6(TP53):c.712T>C (p.Cys238Arg)	SNV	Likely Pathogenic	376576	rs1057519981	GRCh37: 17:7577569-7577569 GRCh38: 17:7674251-7674251
12	TP53	NM_000546.6(TP53):c.824G>A (p.Cys275Tyr)	SNV	Likely Pathogenic	215997	rs863224451	GRCh37: 17:7577114-7577114 GRCh38: 17:7673796-7673796
13	TP53	NM_000546.6(TP53):c.841G>C (p.Asp281His)	SNV	Likely Pathogenic	376588	rs764146326	GRCh37: 17:7577097-7577097 GRCh38: 17:7673779-7673779
14	TP53	NM_000546.6(TP53):c.713G>T (p.Cys238Phe)	SNV	Likely Pathogenic	376574	rs730882005	GRCh37: 17:7577568-7577568 GRCh38: 17:7674250-7674250
15	PTPN11	NM_002834.5(PTPN11):c.226G>A (p.Glu76Lys)	SNV	Likely Pathogenic	13336	rs121918464	GRCh37: 12:112888210-112888210 GRCh38: 12:112450406-112450406
16	TP53	NM_000546.6(TP53):c.395A>G (p.Lys132Arg)	SNV	Likely Pathogenic	376625	rs1057519996	GRCh37: 17:7578535-7578535 GRCh38: 17:7675217-7675217
17	TP53	NM_000546.6(TP53):c.421T>C (p.Cys141Arg)	SNV	Likely Pathogenic	376565	rs1057519978	GRCh37: 17:7578509-7578509 GRCh38: 17:7675191-7675191
18	TP53	NM_000546.6(TP53):c.423C>G (p.Cys141Trp)	SNV	Likely Pathogenic	376564	rs1057519977	GRCh37: 17:7578507-7578507 GRCh38: 17:7675189-7675189
19	TP53	NM_000546.6(TP53):c.842A>G (p.Asp281Gly)	SNV	Likely Pathogenic	141141	rs587781525	GRCh37: 17:7577096-7577096 GRCh38: 17:7673778-7673778
20	BRAF	NM_004333.6(BRAF):c.1787G>T (p.Gly596Val)	SNV	Likely Pathogenic	40387	rs397507483	GRCh37: 7:140453148-140453148 GRCh38: 7:140753348-140753348
21	TP53	NM_000546.6(TP53):c.742C>G (p.Arg248Gly)	SNV	Likely Pathogenic	376652	rs121912651	GRCh37: 17:7577539-7577539 GRCh38: 17:7674221-7674221
22	TP53	NM_000546.6(TP53):c.743G>A (p.Arg248Gln)	SNV	Likely Pathogenic	12356	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
23	TP53	NM_000546.6(TP53):c.394A>G (p.Lys132Glu)	SNV	Likely Pathogenic	376626	rs747342068	GRCh37: 17:7578536-7578536 GRCh38: 17:7675218-7675218
24	TP53	NM_000546.6(TP53):c.451C>T (p.Pro151Ser)	SNV	Likely Pathogenic	12370	rs28934874	GRCh37: 17:7578479-7578479 GRCh38: 17:7675161-7675161
25	CDK4	NM_000075.4(CDK4):c.70C>T (p.Arg24Cys)	SNV	Likely Pathogenic	16928	rs11547328	GRCh37: 12:58145431-58145431 GRCh38: 12:57751648-57751648
26	TP53	NM_000546.6(TP53):c.833C>A (p.Pro278His)	SNV	Likely Pathogenic	376646	rs876659802	GRCh37: 17:7577105-7577105 GRCh38: 17:7673787-7673787
27	TP53	NM_000546.6(TP53):c.815T>G (p.Val272Gly)	SNV	Likely Pathogenic	233323	rs876660333	GRCh37: 17:7577123-7577123 GRCh38: 17:7673805-7673805
28	TP53	NM_000546.6(TP53):c.451C>G (p.Pro151Ala)	SNV	Likely Pathogenic	376641	rs28934874	GRCh37: 17:7578479-7578479 GRCh38: 17:7675161-7675161
29	TP53	NM_000546.6(TP53):c.585C>G (p.Ile195Met)	SNV	Likely Pathogenic	376620	rs1057519994	GRCh37: 17:7578264-7578264 GRCh38: 17:7674946-7674946
30	TP53	NM_000546.6(TP53):c.832C>A (p.Pro278Thr)	SNV	Likely Pathogenic	376643	rs17849781	GRCh37: 17:7577106-7577106 GRCh38: 17:7673788-7673788
31	BRAF	NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)	SNV	Likely Pathogenic	13961	rs113488022	GRCh37: 7:140453136-140453136 GRCh38: 7:140753336-140753336
32	TP53	NM_000546.6(TP53):c.613T>A (p.Tyr205Asn)	SNV	Likely Pathogenic	376684	rs1057520008	GRCh37: 17:7578236-7578236 GRCh38: 17:7674918-7674918
33	TP53	NM_000546.6(TP53):c.742C>T (p.Arg248Trp)	SNV	Likely Pathogenic	12347	rs121912651	GRCh37: 17:7577539-7577539 GRCh38: 17:7674221-7674221
34	TP53	NM_000546.6(TP53):c.842A>T (p.Asp281Val)	SNV	Likely Pathogenic	182968	rs587781525	GRCh37: 17:7577096-7577096 GRCh38: 17:7673778-7673778
35	TP53	NM_000546.6(TP53):c.712T>G (p.Cys238Gly)	SNV	Likely Pathogenic	376577	rs1057519981	GRCh37: 17:7577569-7577569 GRCh38: 17:7674251-7674251
36	TP53	NM_000546.6(TP53):c.817C>A (p.Arg273Ser)	SNV	Likely Pathogenic	376656	rs121913343	GRCh37: 17:7577121-7577121 GRCh38: 17:7673803-7673803
37	TP53	NM_000546.6(TP53):c.451C>A (p.Pro151Thr)	SNV	Likely Pathogenic	12369	rs28934874	GRCh37: 17:7578479-7578479 GRCh38: 17:7675161-7675161
38	TP53	NM_000546.6(TP53):c.583A>T (p.Ile195Phe)	SNV	Likely Pathogenic	376617	rs942158624	GRCh37: 17:7578266-7578266 GRCh38: 17:7674948-7674948
39	TP53	NM_000546.6(TP53):c.587G>C (p.Arg196Pro)	SNV	Likely Pathogenic	231165	rs483352697	GRCh37: 17:7578262-7578262 GRCh38: 17:7674944-7674944
40	TP53	NM_000546.6(TP53):c.818G>T (p.Arg273Leu)	SNV	Likely Pathogenic	376655	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
41	TP53	NM_000546.6(TP53):c.832C>G (p.Pro278Ala)	SNV	Likely Pathogenic	376645	rs17849781	GRCh37: 17:7577106-7577106 GRCh38: 17:7673788-7673788
42	TP53	NM_000546.6(TP53):c.584T>A (p.Ile195Asn)	SNV	Likely Pathogenic	376618	rs760043106	GRCh37: 17:7578265-7578265 GRCh38: 17:7674947-7674947
43	TP53	NM_000546.6(TP53):c.713G>A (p.Cys238Tyr)	SNV	Likely Pathogenic	182935	rs730882005	GRCh37: 17:7577568-7577568 GRCh38: 17:7674250-7674250
44	TP53	NM_000546.6(TP53):c.422G>A (p.Cys141Tyr)	SNV	Likely Pathogenic	140801	rs587781288	GRCh37: 17:7578508-7578508 GRCh38: 17:7675190-7675190
45	TP53	NM_000546.6(TP53):c.743G>T (p.Arg248Leu)	SNV	Likely Pathogenic	230253	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
46	HRAS, LRRC56	NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)	SNV	Likely Pathogenic	12602	rs104894229	GRCh37: 11:534289-534289 GRCh38: 11:534289-534289
47	TP53	NM_000546.6(TP53):c.614A>G (p.Tyr205Cys)	SNV	Likely Pathogenic	376681	rs1057520007	GRCh37: 17:7578235-7578235 GRCh38: 17:7674917-7674917
48	TP53	NM_000546.6(TP53):c.843C>G (p.Asp281Glu)	SNV	Likely Pathogenic	376587	rs1057519984	GRCh37: 17:7577095-7577095 GRCh38: 17:7673777-7673777
49	TP53	NM_000546.6(TP53):c.814G>A (p.Val272Met)	SNV	Likely Pathogenic	185814	rs121912657	GRCh37: 17:7577124-7577124 GRCh38: 17:7673806-7673806
50	TP53	NM_000546.6(TP53):c.824G>C (p.Cys275Ser)	SNV	Likely Pathogenic	376583	rs863224451	GRCh37: 17:7577114-7577114 GRCh38: 17:7673796-7673796

Copy number variations for Plasma Cell Neoplasm from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	17396	1	142600000	155000000	Gain		Plasma-cell dyscrasia

Sources

Expression for Plasma Cell Neoplasm

Search GEO for disease gene expression data for Plasma Cell Neoplasm.

Sources

Pathways for Plasma Cell Neoplasm

Pathways related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 78)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.82	TP53 NRAS KRAS HRAS FLT3 FGFR3
2	Signal Transduction ⁶⁶	13.8	CDK4 CYLD FGFR3 FLT3 HRAS KRAS
3	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.72	TP53 NRAS KRAS HRAS FLT3 FGFR3
4	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.47	ATM CDK4 CDKN2C FGFR3 HRAS KRAS
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.43	YAP1 TP53 NRAS MYD88 KRAS HRAS
6	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.43	ATM B2M CDK4 CRBN DNMT3A FGFR3
7	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.36	TP53 NRAS MYD88 KRAS HRAS FLT3
8	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.91	TP53 NRAS KRAS HRAS FLT3 FGFR3
9	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.84	YAP1 NRAS KRAS HRAS FLT3 FGFR3
10	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.78	TP53 NRAS MYD88 KRAS HRAS CYLD
11	Insulin receptor signalling cascade ⁶⁶ Show member pathways Glucose homeostasis ⁷⁴ IGF1R signaling cascade ⁶⁶ IRS activation ⁶⁶ IRS-mediated signalling ⁶⁶ IRS-related events triggered by IGF1R ⁶⁶ PI3K Cascade ⁶⁶ SHC-related events triggered by IGF1R ⁶⁶ Signal attenuation ⁶⁶ Signaling by Insulin receptor ⁶⁶ Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) ⁶⁶ SOS-mediated signalling ⁶⁶	12.74	NRAS KRAS HRAS FLT3 FGFR3
12	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.7	TP53 NRAS KRAS HRAS FGFR3 CDK4
13	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.66	TP53 NRAS KRAS HRAS FGFR3 ATM
14	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.63	YAP1 TP53 NRAS KRAS HRAS
15	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.53	TP53 NRAS KRAS HRAS
16	Malignant pleural mesothelioma ⁷⁴	12.48	YAP1 TP53 HRAS FLT3 FGFR3 CDK4
17	DNA Damage ³	12.44	ATM AURKA CDK4 CDKN2C LIG4 TP53
18	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.42	NRAS KRAS HRAS FLT3 FGFR3
19	MAPK signaling pathway ⁷⁴	12.42	TP53 NRAS KRAS HRAS FGFR3
20	Development FGFR signaling pathway ²² Show member pathways Development FGF-family signaling ²² Development Flt3 signaling ²² FGF Pathway ⁶⁴	12.38	NRAS KRAS HRAS FLT3 FGFR3
21	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.32	TP53 NRAS KRAS HRAS FGFR3 ATM
22	Signaling by FGFR2 ⁶⁶ Show member pathways FGFR2 ligand binding and activation ⁶⁶ FGFR2b ligand binding and activation ⁶⁶ Signaling by FGFR ⁶⁶	12.31	NRAS KRAS HRAS FGFR3
23	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.29	TP53 CDKN2C CDK4 ATM
24	VEGF Signaling Pathway ⁶⁰ ⁶⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ⁷⁴ TGF-beta Signaling ⁶⁷	12.25	FGFR3 HRAS KRAS NRAS
25	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.23	TP53 NRAS KRAS HRAS FGFR3 CDK4
26	NGF Pathway ⁶⁴ Show member pathways MAPK and NFkB signaling pathways inhibited by Yersinia YopJ ⁷⁴ TRKA Signaling ⁶⁴	12.22	TP53 NRAS KRAS HRAS
27	Signaling by FGFR2 in disease ⁶⁶ Show member pathways FGFR2 mutant receptor activation ⁶⁶ Signaling by FGFR in disease ⁶⁶ Signaling by FGFR2 IIIa TM ⁶⁶	12.21	NRAS KRAS HRAS FGFR3
28	Ras signaling ⁷⁴	12.21	FGFR3 FLT3 HRAS KRAS NRAS
29	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ Signaling by Non-Receptor Tyrosine Kinases ⁶⁶	12.2	NRAS KRAS HRAS CDK4
30	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.19	TP53 MYD88 HRAS CDK4
31	FLT3 signaling in disease ⁶⁶ Show member pathways FLT3 Signaling ⁶⁶ FLT3 signaling by CBL mutants ⁶⁶ FLT3 signaling through SRC family kinases ⁶⁶ Negative regulation of FLT3 ⁶⁶ Signaling by FLT3 fusion proteins ⁶⁶ Signaling by FLT3 ITD and TKD mutants ⁶⁶ STAT5 Activation ⁶⁶ STAT5 activation downstream of FLT3 ITD mutants ⁶⁶	12.17	FLT3 HRAS KRAS NRAS
32	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ G1-S Phase Transition ⁶⁴	12.15	TP53 CDKN2C CDK4 ATM
33	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.14	TP53 NRAS KRAS HRAS FGFR3 CDK4
34	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.1	YAP1 NRAS KRAS HRAS
35	Integrated breast cancer pathway ⁷⁴	12.1	TP53 KRAS CDK4 AURKA ATM
36	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.93	NRAS KRAS HRAS
37	Signaling by EGFR ⁶⁶ Show member pathways EGFR downregulation ⁶⁶ GAB1 signalosome ⁶⁶	11.92	NRAS KRAS HRAS
38	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.92	YAP1 TP53 ATM
39	Signaling by Erythropoietin ⁶⁶ Show member pathways EPO signaling pathway ⁶¹ Erythropoietin activates Phosphoinositide-3-kinase (PI3K) ⁶⁶ Erythropoietin activates Phospholipase C gamma (PLCG) ⁶⁶ Erythropoietin activates RAS ⁶⁶ Erythropoietin activates STAT5 ⁶⁶	11.9	NRAS KRAS HRAS
40	FGFR1 mutant receptor activation ⁶⁶ Show member pathways Signaling by cytosolic FGFR1 fusion mutants ⁶⁶ Signaling by FGFR1 in disease ⁶⁶ Signaling by plasma membrane FGFR1 fusions ⁶⁶	11.88	HRAS KRAS NRAS
41	Signaling by PDGF ⁶⁶ Show member pathways Downstream signal transduction ⁶⁶	11.86	NRAS KRAS HRAS
42	FCERI mediated Ca+2 mobilization ⁶⁶ Show member pathways CLEC7A (Dectin-1) induces NFAT activation ⁶⁶ FCERI mediated MAPK activation ⁶⁶	11.81	NRAS KRAS HRAS
43	Burn wound healing ⁷⁴	11.79	TP53 MYD88 FGFR3
44	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.79	HRAS KRAS NRAS TP53
45	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.78	FLT3 HRAS KRAS NRAS
46	DNA damage response (only ATM dependent) ⁷⁴	11.77	ATM HRAS KRAS NRAS TP53
47	DAP12 interactions ⁶⁶ Show member pathways DAP12 signaling ⁶⁶	11.75	NRAS KRAS HRAS B2M
48	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.71	TP53 HRAS ATM
49	Serotonin HTR1 group and FOS pathway ⁷⁴ Show member pathways Serotonin receptor 2 and ELK-SRF/GATA4 signaling ⁷⁴ Serotonin receptor 4/6/7 and NR3C signaling ⁷⁴	11.7	HRAS KRAS NRAS
50	Prader-Willi and Angelman syndrome ⁷⁴	11.69	TP53 CDKN2C CDK4

Sources

GO Terms for Plasma Cell Neoplasm

Biological processes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell population proliferation	GO:0008284	10.29	YAP1 KRAS HRAS FLT3 FGFR3 CDK4
2	positive regulation of gene expression	GO:0010628	10.28	YAP1 TP53 MYD88 KRAS HRAS ATM
3	MAPK cascade	GO:0000165	10.13	NRAS KRAS HRAS FGFR3
4	T cell differentiation in thymus	GO:0033077	9.97	B2M LIG4 TP53
5	Ras protein signal transduction	GO:0007265	9.97	TP53 NRAS KRAS HRAS
6	fibroblast proliferation	GO:0048144	9.95	TP53 LIG4 HRAS
7	cell population proliferation	GO:0008283	9.95	CDKN2C KRAS LIG4 TP53 YAP1
8	cell cycle	GO:0007049	9.93	ATM AURKA CDK4 CDKN2C CYLD LIG4
9	response to ionizing radiation	GO:0010212	9.91	ATM DNMT3A LIG4
10	phosphorylation	GO:0016310	9.91	FLT3 FGFR3 CDKN2C CDK4 AURKA ATM
11	regulation of cell population proliferation	GO:0042127	9.8	YAP1 TP53 MYD88 HRAS FLT3
12	stem cell proliferation	GO:0072089	9.8	YAP1 TP53 LIG4 CDKN2C
13	pro-B cell differentiation	GO:0002328	9.76	LIG4 FLT3
14	cellular response to gamma radiation	GO:0071480	9.56	YAP1 TP53 HRAS ATM
15	neuron apoptotic process	GO:0051402	9.32	TP53 LIG4 KRAS HRAS ATM

Molecular functions related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	G protein activity	GO:0003925	9.63	NRAS KRAS HRAS
2	kinase activity	GO:0016301	9.43	FLT3 FGFR3 CDKN2C CDK4 AURKA ATM
3	nucleotide binding	GO:0000166	9.28	NRAS LIG4 KRAS HRAS FLT3 FGFR3